这种成分是什么?

이 원료는 다음의 구조를 갖는 지방족 아마이드이다.

成分词典

ERUCAMIDE

Erucamide is a primary fatty amide resulting from the formal condensation of the carboxy group of erucic acid with ammonia.

定义

Erucamide is a primary fatty amide resulting from the formal condensation of the carboxy group of erucic acid with ammonia. It is commonly used as a slip additive in the plastic manufacturing industry. It has a role as an EC 3.1.1.7 (acetylcholinesterase) inhibitor, a mammalian metabolite, a plant metabolite, a human metabolite and a rat metabolite. It is functionally related to an erucic acid.

来源: PubChem

美国FDA 物质登记 · UNII 0V89VY25BN · 登记名称 ERUCAMIDE · 单一化学物质

来源: 美国FDA 物质识别码（UNII）

化妆品中的作用

调节黏度VISCOSITY CONTROLLING使透明剂型变浑浊OPACIFYING

安全与法规参考

未列入韩国有毒物质 GHS 分类 · 现有化学物质

来源: 韩国有毒物质 GHS 信息（环境公团）

详细资料——标示名称、识别编号、物性、试验记录、文献

别名和识别信息

ERUCAMIDEINCI에루카마이드韩国标示名称（食药处标准名）13-Docosenamide, (Z)-同义名

CAS No.化学物质登记号: 3061-72-1
CAS No.化学物质登记号: 112-84-5
EC No.欧盟化学品目录编号: 204-009-2 / 931-599-5
EC No.欧盟化学品目录编号: 931-599-5
EC No.欧盟化学品目录编号: 204-009-2
DTXSID美国EPA化学品编号: DTXSID4026929
DTXCID美国EPA化合物编号: DTXCID606929

IUPAC: (13Z)-Docos-13-enamide
分子式: C22H43NO
分子量: 337.592 g/mol

实测物性

性状: Dry Powder, Large Crystals, Other Solid, CBI · Solid, [Hawley] Off-white beads with a fatty odor, [MSDSonline]
熔点: 75-80 °C
溶解性: SOL IN ISOPROPANOL, SLIGHTLY SOL IN ALCOHOL, ACETONE
熔点/凝固点: 77.5 ℃
初沸点和沸程: 460~488 ℃
闪点: 221~261 ℃ (计算值)
蒸气压: 0.00000000582 ㎜Hg (@ 25 ℃, 估算值)
溶解度: 0.2 ㎎/ℓ (@ 25 ℃, 估算值)
蒸气密度: 11.65
比重: 0.908 (@ 20 ℃)
正辛醇/水分配系数（Kow）: 5.3 (估算值)
分子量: 337.56

这是对物质本身测得的数值。韩国安全保健公团（KOSHA）的资料仅供编写和审核安全数据表参考，并非原料商品的规格。

来源: PubChem · 韩国安全保健公团安全数据表

产品实际使用的用途

这是向美国 EPA 申报含该成分的 38 款产品的用途。其中包括化妆品以外的产品，排在前几行的即为该成分的主要用途。

Anti-adhesive/cohesive19
Lubricating agent7
Processing aids not otherwise specified3
Anti-slip agent3
Hardener2
Anti-static agent1
Wetting agent (non-aqueous)1
Opacifer1

其余用途 1 项

Viscosity modifier1

来源: 美国EPA CompTox

刺激与致敏试验记录

记录有皮肤试验 4 项、眼部试验 2 项。

归类为低4 项

试验结论基本一致（100%）。这是对原料本身的试验记录，与成品中所含浓度下的刺激性不同。

查看全部 6 项试验

Not likely to be sensitizing
skin sensitisation: in vivo (LLNA) · Screening · according to OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay) (2002) according to EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay) (2008)
Not likely to be sensitizing
skin sensitisation: in vivo (LLNA) · Screening · according to OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) (1984) according to
Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) according to
Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion) according to
Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion) (1984) according to